Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality

Table 2

MSC clinical trials in MI, chronic ischemia, and heart failure. MI, myocardial infarction; IC, intracoronary infusion; DI, direct intramyocardial injection; IV, intravenous infusion; TESI, transendocardial stem cell injection; EMG; electromechanical guidance; LV, left ventricular; EF, ejection fraction; ESV, end-systolic volume; EDV, end-diastolic volume; ↑, increase; ↓, decrease.

Group	Condition	Dose (cells)	Followup (months)	Results
Chen et al. [104]	Acute MI	8-10×10^9(IC)	3	↑ Myocardial perfusion, ↑ LVEF, and ↓ LV chamber dimensions
Katritsis et al. [151]	Anteroseptal MI	2–4 × 10^6 (IC)	4	↓ Wall motion score index and ↑ myocardial viability and contractility
Mohyeddin-Bonab et al. [153]	Old MI	2.1-9.1×10^6 (IC)/(DI)	6–18	↓ Perfusion defect and ↑ LVEF
Osiris therapeutics [146]	Acute MI	(IV)	6	↑ Heart function and ↓ arrhythmic events
Hare et al. [103]	Acute MI	0.5, 1.6, and 5 × 10^6 (IV)	3	↑ LVEF and ↓ ventricular arrhythmia
Williams et al. [105]	Chronic ischemic cardiomyopathy secondary to MI	10 repeated injections of 0.5 mL of cell suspension (TESI)	3–12	↓ Cardiac remodeling, ↓ ESV and EDV, and ↑ regional contractility
Bartunek et al. [154] (C-CURE)	Heart failure secondary to ischemic cardiomyopathy	6-12×10^8 (EMG)	6	↑ LVEF and ↓ ESV and EDV